Sumitomo Chemical and Pharma Unveil New Joint Venture in Regenerative Medicine

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=sh5jJYRrX5Y

Sumitomo Chemical Co., Ltd. and Sumitomo Pharma Co., Ltd. have formed a joint venture, RACTHERA Co., Ltd., to advance regenerative medicine and cell therapy. Starting operations in February 2025, the venture will focus on developing cutting-edge therapies in a rapidly growing market, projected to reach $2.0 billion in 2022. Sumitomo Pharma’s expertise in iPS cell technology and Sumitomo Chemical’s capabilities in industrial engineering will drive innovation and speed up global expansion in this field. The joint venture aims to be worth 350 billion yen by the late 2030s, positioning both companies as leaders in transformative medical treatments. • For further information visit: https://www.chemanalyst.com/ • Follow us on LinkedIn: / chemanalyst • For business inquiries: [email protected] • #SumitomoChemical #SumitomoPharma #jointventure #celltherapy

#############################

New on site